Osaka, Japan

Eri Ooboki


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2017-2019

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Eri Ooboki: Innovator in Pharmaceutical Compounds

Introduction

Eri Ooboki is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address critical health issues. With a total of 2 patents, her work is recognized for its potential impact on the treatment of obesity and diabetes.

Latest Patents

Ooboki's latest patents include an aromatic heterocyclic compound that is represented by a specific general formula. This compound features a benzene ring that may be substituted, along with other components that contribute to its efficacy. The compound is designed to serve as a prevention and treatment agent for obesity, diabetes, and related conditions. The innovative nature of her work highlights the importance of chemical compounds in addressing prevalent health challenges.

Career Highlights

Eri Ooboki is currently employed at Mitsubishi Tanabe Pharma Corporation, where she continues to advance her research and development efforts. Her role at the company allows her to collaborate with other experts in the field and contribute to groundbreaking pharmaceutical innovations.

Collaborations

Ooboki has worked alongside notable colleagues, including Kunio Saruta and Norimitsu Hayashi. These collaborations have fostered a dynamic environment for innovation and have enhanced the quality of research conducted at Mitsubishi Tanabe Pharma Corporation.

Conclusion

Eri Ooboki's contributions to the pharmaceutical industry through her innovative patents demonstrate her commitment to improving health outcomes. Her work not only showcases her expertise but also emphasizes the importance of collaboration in driving advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…